Parsatuzumab Reference: HY-P99215 Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition.
Naveni TriFlex Cell MR Reference: 60024 Detect and quantify total protein A, total protein B, and the interaction AB between the two proteins. The assay is designed to be used with a mouse and rabbit primary antibody pair.
Nimotuzumab Reference: HY-P9968 Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor agent, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC).
NaveniLink Reference: 60028 Conjugate your own primary antibodies. The NaveniLink kit is for conjugating oligos and primary antibodies for the creation of Navenibodies. The kit is compatible with NaveniFlex Cell, NaveniFlex Tissue and NaveniBright
Domagrozumab Reference: HY-P99857 Domagrozumab is an anti-myostatin humanized monoclonal antibody with a KD value of 2.6 pM for human myostatin. Domagrozumab induces muscle anabolic activity. Domagrozumab can be used in research of duchenne muscular dystrophy (DMD).
NaveniFlex control kit Reference: 60029 Control kit to identify positive signals in proximity ligation assays. Use together with NaveniFlex Cell/Tissue/Bright MR.
Zolbetuximab Reference: HY-P99058 Zolbetuximab (IMAB362) is a monoclonal antibody targeting Claudin-18.2. Zolbetuximab mediates specific killing of Claudin-18.2-positive cells through immune effector mechanisms. Zolbetuximab can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors.
Naveni PD1/PD-L1 HRP Reference: 60033 Visualize the interaction of PD1 and PD-L1 in situ. The kit includes primary Navenibodies specific to PD1 and PD-L1, and all other reagents needed to run the assay. Chromogenic detection and bright-field read-out